Earnings guidance

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of NSP and FE of Upcoming Deadlines

Tuesday, August 11, 2020 - 4:30am

Likewise, on April 29, 2019, Insperity reported record first quarter results, and raised its full-year 2019 guidance.

Key Points: 
  • Likewise, on April 29, 2019, Insperity reported record first quarter results, and raised its full-year 2019 guidance.
  • As a result, Insperitys stock price dramatically increased during the first half of 2019.
  • Despite delivering year-over-year growth and meeting analysts estimates, the Company offered disappointing third quarter 2019 guidance and reduced its full-year 2019 guidance.
  • Finally, on February 11, 2020, after the close of trading, Insperity released its fourth quarter and full-year 2019 financial results.

Organogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results

Monday, August 10, 2020 - 9:05pm

Operating expenses for the six months ended June 30, 2020 were $109.2 million, compared to $105.1 million for the first six months of 2019, an increase of $4.1 million, or 4%.

Key Points: 
  • Operating expenses for the six months ended June 30, 2020 were $109.2 million, compared to $105.1 million for the first six months of 2019, an increase of $4.1 million, or 4%.
  • Fiscal Year 2020 Revenue Guidance:
    The Company is reinstating its fiscal year 2020 revenue guidance, originally issued on March 9, 2020.
  • Second Quarter 2020 Earnings Conference Call:
    Financial results for the second fiscal quarter of 2020 will be reported after the market closes on Monday, August 10, 2020.
  • Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

CommScope Reports Second Quarter 2020 Results

Thursday, August 6, 2020 - 11:00am

Due to the significant and evolving uncertainties related to the impact of the COVID-19 pandemic, CommScope is providing limited financial guidance for 2020.

Key Points: 
  • Due to the significant and evolving uncertainties related to the impact of the COVID-19 pandemic, CommScope is providing limited financial guidance for 2020.
  • While the Company is not providing specific guidance for the third quarter, the Company expects its third quarter sales and non-GAAP adjusted EBITDA to improve modestly compared to the second quarter.
  • ET in which management will discuss second quarter 2020 results.
  • These and other factors are discussed in greater detail in our 2019 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and may be updated from time to time in our annual reports, quarterly reports, current reports and other filings we make with the Securities and Exchange Commission.

ALLETE, Inc. Reports Second Quarter Earnings

Wednesday, August 5, 2020 - 11:30am

ALLETE, Inc. (NYSE: ALE) today reported second quarter 2020 earnings of 39 cents per share on net income of $20.1 million.

Key Points: 
  • ALLETE, Inc. (NYSE: ALE) today reported second quarter 2020 earnings of 39 cents per share on net income of $20.1 million.
  • Results in the second quarter of 2020 included a 16 cent per share charge for the recent Minnesota Power rate case resolution.
  • Results in the second quarter of 2019 included 2 cents per share of a U.S. Water Services gain on sale adjustment.
  • See page 4 in this release for a reconciliation of 2020 annual GAAP earnings guidance range to 2020 annual adjusted earnings guidance range (Non-GAAP).

CytoSorbents Reports Record Second Quarter 2020 Financial Results

Tuesday, August 4, 2020 - 9:15pm

That said, we have not historically given specific financial guidance on quarterly results until the quarter has been completed.

Key Points: 
  • That said, we have not historically given specific financial guidance on quarterly results until the quarter has been completed.
  • Though difficult to quantitate, we estimate that approximately $2.4 to $2.6 million of total product sales in the second quarter of 2020 was due to the demand for CytoSorb to treat COVID-19 patients.
  • The 2020 gain was directly related to the increase in the spot exchange rate of the Euro to the U.S. dollar at June 30, 2020 as compared to March 31, 2020.
  • CytoSorbents has not historically given specific financial guidance on quarterly results until the quarter has been completed.

Luminex Corporation Reports Second Quarter 2020 Results

Tuesday, August 4, 2020 - 9:01pm

The conference call will be webcast live and may be accessed at Luminex Corporation's website at investor.luminexcorp.com.

Key Points: 
  • The conference call will be webcast live and may be accessed at Luminex Corporation's website at investor.luminexcorp.com.
  • Analysts may participate on the conference call by dialing (877) 930-7053 (U.S.) or (253) 336-7290 (outside the U.S.).
  • At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.
  • Forward-looking statements in this release include statements regarding expected revenue and cost savings and projected 2020 performance, including revenue guidance.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of NSP and FE of Upcoming Deadlines

Tuesday, August 4, 2020 - 4:30am

Likewise, on April 29, 2019, Insperity reported record first quarter results, and raised its full-year 2019 guidance.

Key Points: 
  • Likewise, on April 29, 2019, Insperity reported record first quarter results, and raised its full-year 2019 guidance.
  • As a result, Insperitys stock price dramatically increased during the first half of 2019.
  • Despite delivering year-over-year growth and meeting analysts estimates, the Company offered disappointing third quarter 2019 guidance and reduced its full-year 2019 guidance.
  • Finally, on February 11, 2020, after the close of trading, Insperity released its fourth quarter and full-year 2019 financial results.

PREIT Schedules Second Quarter 2020 Earnings Release and Conference Call

Monday, August 3, 2020 - 9:30pm

PHILADELPHIA, Aug. 3, 2020 /PRNewswire/ -- Pennsylvania Real Estate Investment Trust (PREIT/NYSE: PEI) intends to release its financial results for the quarter ending June 30, 2020 after market trading closes on Monday, August 10, 2020.

Key Points: 
  • PHILADELPHIA, Aug. 3, 2020 /PRNewswire/ -- Pennsylvania Real Estate Investment Trust (PREIT/NYSE: PEI) intends to release its financial results for the quarter ending June 30, 2020 after market trading closes on Monday, August 10, 2020.
  • As previously announced, and due to COVID-19, the Company has withdrawn its full-year 2020 guidance issued on February 25, 2020.
  • The Company is not providing updated guidance in conjunction with its second quarter 2020 earnings results.
  • Management has scheduled a conference call for 9:00 a.m. Eastern Time on TuesdayAugust 11, 2020, to review the Company's results and future outlook.

Insperity Second Quarter Earnings Conference Call Monday, August 3

Thursday, July 23, 2020 - 3:30pm

Insperity, Inc. (NYSE: NSP), a leading provider of human resources and business performance solutions for Americas best businesses, will release its second quarter earnings after the close of the New York Stock Exchange on Monday, August 3, 2020.

Key Points: 
  • Insperity, Inc. (NYSE: NSP), a leading provider of human resources and business performance solutions for Americas best businesses, will release its second quarter earnings after the close of the New York Stock Exchange on Monday, August 3, 2020.
  • Investors, analysts, media and other interested persons may access the call at 877-651-0053, conference i.d.
  • The conference call script and updated company guidance for the third quarter and full year 2020 will be posted to the Insperity Investor Relations website.
  • Insperity business performance solutions support more than 100,000 businesses with over 2 million employees and $4.3 billion in revenue in 2019.

electroCore Provides Business Update and Select Financial Guidance

Tuesday, July 14, 2020 - 9:05pm

BASKING RIDGE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the second quarter and full year 2020.

Key Points: 
  • BASKING RIDGE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the second quarter and full year 2020.
  • These trials are designed to study the potential for gammaCore (nVNS) to treat the respiratory symptoms and underlying inflammation affecting COVID-19 patients.
  • In light of these recent challenges, the trajectory of this business channel remains difficult to forecast into the remainder of the year.
  • electroCore today announced the following preliminary unaudited financial guidance for the second quarter of 2020:
    Q2 2020 revenue: The company expects second quarter 2020 total revenue to be approximately $730,000 to $750,000, as compared to first quarter 2020 total revenue of $734,000.